Plexision, Inc

Plexision develops cellular biomarkers and diagnostic platforms for personalized medicine in solid organ transplantation and immunological disorders. The company specializes in biomarker discovery and validation, offering diagnostic services and R&D support across transplant rejection, viral infections, COVID-19, immune deficiency, and immuno-oncology applications. Plexision's technology platform enables risk assessment for immunological disorders, drug efficacy prediction for patient populations, and dosing optimization for new immunological therapeutics. The company operates a CLIA-certified laboratory in Pittsburgh, PA, supporting both clinical diagnostics and pharmaceutical drug development across preclinical through post-marketing phases. Services include biomarker integration into drug development pipelines and personalized diagnostic testing.